Diffuse Astrocytic and Oligodendroglial Tumors in Adults
Key Points
Key Points
- Each year, more than 15,000 people in the United States are newly diagnosed with diffuse astrocytic and oligodendroglial tumors, including glioblastoma.
- Recently, several systemic agents and a device have demonstrated improvements in survival when added to surgical and radiation therapies.
- Genetic alterations, specifically Isocitrate Dehydrogenase 1 and 2 (IDH1 and IDH2), have become critical classification and prognostic biomarkers.
Treatment
...Treatment...
...IDH-mu...
...Oligodendroglioma, IDH-...
...dation 1.1People with oligodendroglioma, IDH-m...
...de is a reasonable alternative to PCV when to...
...n 1.2Within the group of people with oli...
...Oligodendroglioma, I...
...dation 1.3People with oligodendroglioma, IDH-m...
...s a reasonable alternative to PCV when toxici...
...Astrocy...
...tion 1.4People with astrocytoma, IDH-mut...
...ecommendation 1.5In astrocytoma, IDH-mutant...
...A...
...dation 1.6People with astrocytoma, IDH-mutant, 1p...
...Astrocytoma, IDH...
...1.7People with astrocytoma, IDH-mutant CNS WHO...
...Glioblastoma...
...tion 2.1People with astrocytomas, IDH-w...
...2.2Concurrent temozolomide and rad...
...ecommendation 2.3Six months of adjuvant...
...dation 2.4Alternating electric field therapy may...
...2.5Bevacizumab is NOT recommended...
...mmendation 2.6In people with gliobl...
...tion 2.7In people with glioblastoma, IDH-w...
...commendation 2.8No recommendation for or against...
...h recurrent glioblastoma should be refe...
...ation 2.9No recommendation for or against...
...iffuse midline glioma should be referred f...
Table 1. Reasonable Doses and Schedules by Recommendation
...asonable Doses and Schedules by Reco...